Literature DB >> 18495353

Time-course of SKF-81297-induced increase in glutamic acid decarboxylase 65 and 67 mRNA levels in striatonigral neurons and decrease in GABA(A) receptor alpha1 subunit mRNA levels in the substantia nigra, pars reticulata, in adult rats with a unilateral 6-hydroxydopamine lesion.

N Yamamoto1, J-J Soghomonian.   

Abstract

Striatal projection neurons use GABA as their neurotransmitter and express the rate-limiting synthesizing enzyme glutamic acid decarboxylase (GAD) and the vesicular GABA transporter vGAT. The chronic systemic administration of an agonist of dopamine D1/D5-preferring receptors is known to alter GAD mRNA levels in striatonigral neurons in intact and dopamine-depleted rats. In the present study, the effects of a single or subchronic systemic administration of the dopamine D1/D5-preferring receptor agonist SKF-81297 on GAD65, GAD67, PPD and vGAT mRNA levels in the striatum and GABA(A) receptor alpha1 subunit mRNA levels in the substantia nigra, pars reticulata, were measured in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion. After a single injection of SKF-81297, striatal GAD65 mRNA levels were significantly increased at 3 but not 72 h. In contrast, striatal GAD67 mRNA levels were increased and nigral alpha1 mRNA levels were decreased at 72 but not 3 h. Single cell analysis on double-labeled sections indicated that increased GAD or vGAT mRNA levels after acute SKF-81297 occurred in striatonigral neurons identified by their lack of preproenkephalin expression. Subchronic SKF-81297 induced significant increases in striatal GAD67, GAD65, preprodynorphin and vGAT mRNA levels and decreases in nigral alpha1 mRNA levels. In the striatum contralateral to the 6-OHDA lesion, subchronic but not acute SKF-81297 induced a significant increase in GAD65 mRNA levels. The other mRNA levels were not significantly altered. Finally, striatal GAD67 mRNA levels were negatively correlated with nigral alpha1 mRNA levels in the dopamine-depleted but not dopamine-intact side. The results suggest that different signaling pathways are involved in the modulation by dopamine D1/D5 receptors of GAD65 and GAD67 mRNA levels in striatonigral neurons. They also suggest that the down-regulation of nigral GABA(A) receptors is linked to the increase in striatal GAD67 mRNA levels in the dopamine-depleted striatum.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18495353      PMCID: PMC2483836          DOI: 10.1016/j.neuroscience.2008.04.015

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  54 in total

1.  Synergistically interacting dopamine D1 and NMDA receptors mediate nonvesicular transporter-dependent GABA release from rat striatal medium spiny neurons.

Authors:  A N Schoffelmeer; L J Vanderschuren; T J De Vries; F Hogenboom; G Wardeh; A H Mulder
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  Effect of unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway on GABA(A) receptor subunit gene expression in the rodent basal ganglia and thalamus.

Authors:  A Chadha; L G Dawson; P G Jenner; S Duty
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

3.  The organization of the striatal output system: a single-cell juxtacellular labeling study in the rat.

Authors:  Y Wu; S Richard; A Parent
Journal:  Neurosci Res       Date:  2000-09       Impact factor: 3.304

4.  Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease.

Authors:  A Carta; S Fenu; M Morelli
Journal:  Neurol Sci       Date:  2001-02       Impact factor: 3.307

5.  Systemic administration of dizocilpine maleate (MK-801) or L-dopa reverses the increases in GAD65 and GAD67 mRNA expression in the globus pallidus in a rat hemiparkinsonian model.

Authors:  Jean-Jacques Bacci; Pascal Salin; Lydia Kerkerian-Le Goff
Journal:  Synapse       Date:  2002-12-15       Impact factor: 2.562

6.  Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.

Authors:  Anna R Carta; Annalisa Pinna; Omar Cauli; Micaela Morelli
Journal:  Synapse       Date:  2002-06-01       Impact factor: 2.562

7.  Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.

Authors:  M Andersson; A Hilbertson; M A Cenci
Journal:  Neurobiol Dis       Date:  1999-12       Impact factor: 5.996

8.  D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons.

Authors:  G S Robertson; S R Vincent; H C Fibiger
Journal:  Neuroscience       Date:  1992-07       Impact factor: 3.590

9.  D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase.

Authors:  Charles R Gerfen; Shigehiro Miyachi; Ronald Paletzki; Pierre Brown
Journal:  J Neurosci       Date:  2002-06-15       Impact factor: 6.167

10.  Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.

Authors:  R J Carey
Journal:  Brain Res       Date:  1991-12-24       Impact factor: 3.252

View more
  4 in total

1.  Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.

Authors:  N Yamamoto; J-J Soghomonian
Journal:  Neuroscience       Date:  2009-08-04       Impact factor: 3.590

2.  Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Jessica A George; Karen L Eskow Jaunarajs; Cara M Hueston; Christopher Bishop
Journal:  ACS Chem Neurosci       Date:  2013-04-01       Impact factor: 4.418

3.  Administration of neurotoxic doses of MDMA reduces sensitivity to ethanol and increases GAT-1 immunoreactivity in mice striatum.

Authors:  María Izco; Maria Dolores Gutierrez-Lopez; Ivanny Marchant; Esther O'Shea; Maria Isabel Colado
Journal:  Psychopharmacology (Berl)       Date:  2009-10-20       Impact factor: 4.530

4.  Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.

Authors:  Christopher Bishop; David M Krolewski; Karen L Eskow; Christopher J Barnum; Kristin B Dupre; Terrence Deak; Paul D Walker
Journal:  J Neurosci Res       Date:  2009-05-15       Impact factor: 4.164

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.